Cellectar Biosciences Inc
CLRB5.200USD
-0.290-5.28%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
9.42MMarket Cap
LossP/E TTM
More Details of Cellectar Biosciences Inc Company
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. Its Iopofosine is evaluated in the completed CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstrom’s macroglobulinemia (WM).
Company Info
Ticker SymbolCLRB
Company nameCellectar Biosciences Inc
IPO dateMay 20, 2005
CEOMr. James V. Caruso
Number of employees11
Security typeOrdinary Share
Fiscal year-endMay 20
Address100 Campus Drive
CityFLORHAM PARK
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code07932
Phone16084418120
Websitehttps://www.cellectar.com/
Ticker SymbolCLRB
IPO dateMay 20, 2005
CEOMr. James V. Caruso
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Jarrod Longcor
Mr. Jarrod Longcor
Chief Operating Officer
Chief Operating Officer
12.77K
+360.88%
Mr. James V. Caruso
Mr. James V. Caruso
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
11.64K
+609.38%
Mr. Chad J. Kolean
Mr. Chad J. Kolean
Chief Financial Officer, Vice President, Secretary
Chief Financial Officer, Vice President, Secretary
6.42K
+352.36%
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Independent Chairman of the Board
Independent Chairman of the Board
83.00
--
Mr. Stefan D. Loren, Ph.D.
Mr. Stefan D. Loren, Ph.D.
Independent Director
Independent Director
--
--
Mr. Frederick W. (Fred) Driscoll
Mr. Frederick W. (Fred) Driscoll
Independent Director
Independent Director
--
--
Mr. John P. Neis
Mr. John P. Neis
Independent Director
Independent Director
--
--
Dr. Asher Alban Chanan-Khan, M.D.
Dr. Asher Alban Chanan-Khan, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Jarrod Longcor
Mr. Jarrod Longcor
Chief Operating Officer
Chief Operating Officer
12.77K
+360.88%
Mr. James V. Caruso
Mr. James V. Caruso
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
11.64K
+609.38%
Mr. Chad J. Kolean
Mr. Chad J. Kolean
Chief Financial Officer, Vice President, Secretary
Chief Financial Officer, Vice President, Secretary
6.42K
+352.36%
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Independent Chairman of the Board
Independent Chairman of the Board
83.00
--
Mr. Stefan D. Loren, Ph.D.
Mr. Stefan D. Loren, Ph.D.
Independent Director
Independent Director
--
--
Mr. Frederick W. (Fred) Driscoll
Mr. Frederick W. (Fred) Driscoll
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Sep 6
Updated: Sat, Sep 6
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Hexstone Capital LLC
4.70%
The Vanguard Group, Inc.
1.76%
Geode Capital Management, L.L.C.
0.45%
Longcor (Jarrod)
0.40%
HRT Financial LP
0.39%
Other
92.29%
Shareholders
Shareholders
Proportion
Hexstone Capital LLC
4.70%
The Vanguard Group, Inc.
1.76%
Geode Capital Management, L.L.C.
0.45%
Longcor (Jarrod)
0.40%
HRT Financial LP
0.39%
Other
92.29%
Shareholder Types
Shareholders
Proportion
Corporation
5.00%
Investment Advisor
2.74%
Individual Investor
1.07%
Investment Advisor/Hedge Fund
0.60%
Hedge Fund
0.04%
Bank and Trust
0.04%
Research Firm
0.01%
Other
90.49%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
84
195.80K
7.48%
-354.58K
2025Q1
86
199.12K
11.22%
-346.61K
2024Q4
85
5.89M
13.20%
-10.24M
2024Q3
82
15.21M
37.53%
+860.01K
2024Q2
87
12.77M
37.42%
+1.31M
2024Q1
84
10.31M
32.95%
-1.69M
2023Q4
71
9.17M
43.97%
+2.46M
2023Q3
74
3.14M
32.62%
+389.97K
2023Q2
83
3.71M
38.83%
+394.07K
2023Q1
91
3.81M
40.21%
+165.83K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
57.40K
2.14%
-172.00
-0.30%
Mar 31, 2025
Geode Capital Management, L.L.C.
14.78K
0.55%
+3.08K
+26.38%
Mar 31, 2025
Longcor (Jarrod)
2.77K
0.18%
+1.00K
+56.47%
Apr 17, 2025
HRT Financial LP
1.54K
0.06%
+1.54K
--
Mar 31, 2025
Caruso (James V)
1.64K
0.11%
--
--
Apr 17, 2025
BlackRock Institutional Trust Company, N.A.
7.46K
0.28%
-56.00
-0.75%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jul 21, 2022
Merger
10→1
Jul 21, 2022
Merger
10→1
Jul 21, 2022
Merger
10→1
Jul 21, 2022
Merger
10→1
Date
Type
Ratio
Jul 21, 2022
Merger
10→1
Jul 21, 2022
Merger
10→1
Jul 21, 2022
Merger
10→1
Jul 21, 2022
Merger
10→1
